Niagen Bioscience (NAGE) Capital Expenditures Growth (1y) (2012 - 2020)
Powered by 
Analysis
Niagen Bioscience (NAGE) Capital Expenditures Growth (1y) (2012 - 2020) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -22.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.68% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1,133.33% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -37.81% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 142.64% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 22,433.30% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -73.62% |
| 10 | Niagen Bioscience | 251.05 Mn | 184.31 Mn | 19.31 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2020 | 33.33% |
| Mar 31, 2020 | -93.72% |
| Dec 31, 2019 | 2,700.00% |
| Sep 30, 2019 | 318.92% |
| Jun 30, 2019 | -93.80% |
| Mar 31, 2019 | 48.45% |
| Dec 31, 2018 | -96.61% |
| Sep 30, 2018 | -93.59% |
| Jun 30, 2018 | 736.84% |
| Mar 31, 2018 | -0.62% |
| Dec 30, 2017 | -47.69% |
| Sep 30, 2017 | -18.71% |
| Jul 1, 2017 | -38.02% |
| Apr 1, 2017 | 874.20% |
| Dec 31, 2016 | 19.53% |
| Mar 30, 2013 | 57.57% |
| Dec 29, 2012 | -55.58% |
| Sep 29, 2012 | -93.38% |
| Jun 30, 2012 | -83.06% |
| Mar 31, 2012 | -91.97% |